NCT03177278View on ClinicalTrials.gov

A Study to Assess the Metabolism, Excretion, and Mass Balance of Radio-Labeled Plazomicin

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 16, 2017

Primary Completion Date

July 10, 2017

Study Completion Date

July 10, 2017

Conditions
Healthy Volunteers
Interventions
DRUG

[14C]-plazomicin

single intravenous dose

Trial Locations (1)

68502

Clinical Site, Lincoln

Sponsors

Lead Sponsor

Achaogen, Inc.

Collaborators (1)

Celerion
All Listed Sponsors
collaborator

Celerion

INDUSTRY

lead

Achaogen, Inc.

INDUSTRY

NCT03177278 - A Study to Assess the Metabolism, Excretion, and Mass Balance of Radio-Labeled Plazomicin | Biotech Hunter | Biotech Hunter